Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022 - November 8-12, 2022 / Boston, MA
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Artificial Intelligence–Powered Immune Phenotyping of Advanced or Metastatic Urothelial Carcinoma Clinical Trial Samples from Hematoxylin and Eosin–Stained Whole Slide Images
Conway | Poster #554
First-Line Avelumab Treatment in Patients with Metastatic Merkel Cell Carcinoma: 4-Year Follow-Up from Part B of the JAVELIN Merkel 200 Trial (includes PLS)
D’Angelo | Poster #604
JAVELIN Bladder Medley: A Phase 2 Trial of Avelumab in Combination with Other Antitumor Drugs as First-Line Maintenance Therapy for Advanced Urothelial Carcinoma (includes PLS)
Hoffman-Censits | Poster #665
Evaluation of Novel Anti-TIGIT Antibody M6223 as a Single Agent and in Combination with Avelumab on Human Natural Killer Cell Cytotoxicity
Titov | Poster #432
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: